Skip to main content
BMC Pharmacology logoLink to BMC Pharmacology
. 2009 Aug 11;9(Suppl 1):S13. doi: 10.1186/1471-2210-9-S1-S13

Acute heart failure syndromes

Mihai Gheorghiade 1,
PMCID: PMC3313403

Heart failure resulting in hospitalization represents a significant and growing health care burden. Heterogeneity characterizes this group in terms of mode of presentation, pathophysiology, and prognosis. The vast majority of patients symptomatically improve during hospitalization; however, their early post-discharge rehospitalisation and mortality rates continue to be high. Worsening signs and symptoms, neurohormonal, and renal abnormalities occurring soon after discharge may contribute to these high post-discharge event rates. Currently available assessment modalities combined with recent advances in cardiovascular therapies provide present-day opportunities to improve post-discharge outcomes. Further investigation into pathophysiologic targets and novel approaches to clinical trial design are needed. Improving post-discharge outcomes is the single most important goal in the management of acute heart failure syndromes [1].

References

  1. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol. 2009;53:557–573. doi: 10.1016/j.jacc.2008.10.041. [DOI] [PubMed] [Google Scholar]

Articles from BMC Pharmacology are provided here courtesy of BMC

RESOURCES